Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00033514Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Aug 2001
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in breast cancer, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoints: Objective Response Rate at 5 years and Recommended Dose for Phase II. Started Aug 2001; status: completed.
02
Drugs
erlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00033514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00033514.